🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) Trial

RecruitingPhase 3Ages 18 Years - 75 YearsAllJason Sperry
NCT07212998 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) trial will be a 5-year (3-year enrollment), open label, phase-3, multi-center, early in-hospital phase randomized trial utilizing burn centers from within the LITES network and will enroll approximately 750 injured adult patients who have suffered large 2nd or 3rd degree thermal burns on at least 20% of their body surface requiring burn resuscitation. The objective is to determine if initiating plasma resuscitation as soon as possible upon arrival to an emergency department or burn unit is the most effective resuscitation for those who have experienced large thermal burns and significantly reduces the morbidity and mortality attributable to post-injury complications as compared to standard in-hospital resuscitation practice.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Estimated ≥ 20% Total Body Surface Area burn/thermal injury with 2nd or 3rd degree depth * Anticipated admission to burn ICU Exclusion Criteria: * Estimated rBaux score \<55 * Not expected to survive \>24 hours * Wearing NO PREEVENT opt-out bracelet * Age \> 75 or \< 18 years of age * Concomitant traumatic injury with hemorrhagic shock * Isolated chemical burn/injury * Isolated deep electrical burn/injury * Known prisoner * Known pregnancy * Cardiac arrest with \> 5 continuous minutes of CPR * Concern for anoxic injury/ fixed pupils bilaterally * Objection to study voiced by subject or family member at the scene or at the emergency department/burn center
💊

What it tests

  • Plasma
  • Standard care
📍

Where

1 site
University of Pittsburgh
Pittsburgh, United States
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy